Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss A Practice Change for ALK+ Lung Cancer Patients, Alecensa for First Line Treatment.
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses Liquid Biopsies for Broad Next Generation Sequencing Testing.
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses Liquid Biopsies for EGFR.
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses the Role for Immunotherapy for Patients with Driver Mutations.
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses Multiple Immunotherapy Agents.
This is a slide presentation I did last week at a local conference, describing the steady, incremental improvements in survival with advanced...
Dr. Charles Rudin of Memorial Sloan Kettering talks about RAF and other genetic mutations that play a role in the growth of lung cancer. February 2014...
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute talks about exciting new developments which will allow oncologists to test patients' lung tumors...
Dr. Charles Rudin of Memorial Sloan Kettering on how PARP inhibitors may benefit patients with small cell lung cancer. February 2014. [powerpress]
Dr. Cathy Pietanza of Memorial Sloan Kettering on the new avenues of research into the treatment of small cell lung cancer. February 2014. [powerpress...
An FDA press release states that: "On August 16, 2018, the Food and Drug Administration granted accelerated approval to nivolumab (Opdivo, Bristol...
Dear Moderators and Doctors I’ve read number of exiting articles published by Spanish group about Silibinin, which is extract of milk thistle. Those...
I was reading the article by Dr West, How long should we continue immune checkpoint inhibitor therapy in patients who respond? This was written in...
I was reading the article by Dr West, How long should we continue immune checkpoint inhibitor therapy in patients who respond? This was written in...
Dr. West or other oncologist: I am a 60 yo, post-14 yr stage 2 breast cancer patient. I went to my oncologist in March with a complaint of an off and...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.